Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 USD | +4.60% | -20.87% | -21.89% |
Jun. 13 | Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202 | CI |
Jun. 07 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.89% | 25.28M | |
+51.63% | 798B | |
+41.51% | 633B | |
-5.10% | 356B | |
+19.90% | 328B | |
+9.95% | 304B | |
+17.66% | 244B | |
+3.39% | 227B | |
+10.75% | 216B | |
+6.99% | 166B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. Provides Earnings Guidance for the Quarter Ended December 31, 2020